180 related articles for article (PubMed ID: 7905276)
1. Possible coexistence of two independent mechanisms contributing to anthracycline resistance in leukaemia P388 cells.
Soto F; Planells-Cases R; Canaves JM; Ferrer-Montiel AV; Aleu J; Gamarro F; Castanys S; Gonzalez-Ros JM; Ferragut JA
Eur J Cancer; 1993; 29A(15):2144-50. PubMed ID: 7905276
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of P-glycoprotein and alterations in topoisomerase II in P388 mouse leukemia cells selected in vivo for resistance to mitoxantrone.
Kamath N; Grabowski D; Ford J; Kerrigan D; Pommier Y; Ganapathi R
Biochem Pharmacol; 1992 Sep; 44(5):937-45. PubMed ID: 1356339
[TBL] [Abstract][Full Text] [Related]
3. Effect of Calphostin C (PKC inhibitor) on daunorubicin resistance in P388/ADR and HL60/AR cells: reversal of drug resistance possibly via P-glycoprotein.
Gupta S; Patel K; Singh H; Gollapudi S
Cancer Lett; 1994 Jan; 76(2-3):139-45. PubMed ID: 7511983
[TBL] [Abstract][Full Text] [Related]
4. Partial circumvention of P-glycoprotein-mediated multidrug resistance by doxorubicin-14-O-hemiadipate.
Leontieva OV; Preobrazhenskaya MN; Bernacki RJ
Invest New Drugs; 2002 Feb; 20(1):35-48. PubMed ID: 12003193
[TBL] [Abstract][Full Text] [Related]
5. Probing daunorubicin accumulation defects in non-P-glycoprotein expressing multidrug-resistant cell lines using digitonin.
Versantvoort CH; Broxterman HJ; Feller N; Dekker H; Kuiper CM; Lankelma J
Int J Cancer; 1992 Apr; 50(6):906-11. PubMed ID: 1348241
[TBL] [Abstract][Full Text] [Related]
6. MDR-1 gene expression, anthracycline retention and cytotoxicity in human lung-tumor cells from refractory patients.
Ramachandran C; Sauerteig A; Sridhar KS; Thurer RJ; Krishan A
Cancer Chemother Pharmacol; 1993; 31(6):431-41. PubMed ID: 8095859
[TBL] [Abstract][Full Text] [Related]
7. Verapamil reverses the ultrastructural alterations in the plasma membrane induced by drug resistance.
García-Segura LM; Soto F; Planells-Cases R; Gonzalez-Ros JM; Ferragut JA
FEBS Lett; 1992 Dec; 314(3):404-8. PubMed ID: 1468576
[TBL] [Abstract][Full Text] [Related]
8. Extent and persistence of P-glycoprotein inhibition in multidrug-resistant P388 cells after exposure to resistance-modifying agents.
Boesch D; Loor F
Anticancer Drugs; 1994 Apr; 5(2):229-38. PubMed ID: 7914109
[TBL] [Abstract][Full Text] [Related]
9. Comparative studies of the uptake of daunorubicin in sensitive and resistant P388 cell lines by flow cytometry and biochemical extraction procedures.
McGown AT; Ward TH; Fox BW
Cancer Chemother Pharmacol; 1983; 11(2):113-6. PubMed ID: 6627597
[TBL] [Abstract][Full Text] [Related]
10. Different distribution of daunomycin in plasma membranes from drug-sensitive and drug-resistant P388 leukemia cells.
Ferrer-Montiel AV; Gonzalez-Ros JM; Ferragut JA
Biochim Biophys Acta; 1992 Feb; 1104(1):111-6. PubMed ID: 1550837
[TBL] [Abstract][Full Text] [Related]
11. Protein kinase C isoforms in multidrug resistant P388/ADR cells: a possible role in daunorubicin transport.
Gollapudi S; Patel K; Jain V; Gupta S
Cancer Lett; 1992 Feb; 62(1):69-75. PubMed ID: 1347251
[TBL] [Abstract][Full Text] [Related]
12. Resistance to purine and pyrimidine nucleoside and nucleobase analogs by the human MDR1 transfected murine leukemia cell line L1210/VMDRC.06.
Zeng H; Lin ZP; Sartorelli AC
Biochem Pharmacol; 2004 Sep; 68(5):911-21. PubMed ID: 15294454
[TBL] [Abstract][Full Text] [Related]
13. Chemomodulation of drugs involved in multidrug resistance in chronic lymphatic leukemia of the B-cell type.
Reichle A; Diddens H; Altmayr F; Rastetter J; Andreesen R
Cancer Chemother Pharmacol; 1994; 34(4):307-16. PubMed ID: 7913420
[TBL] [Abstract][Full Text] [Related]
14. P-glycoprotein expression and modulation of cell-membrane morphology in adriamycin-resistant P388 leukemia cells.
Radel S; Fredericks W; Mayhew E; Baker R
Cancer Chemother Pharmacol; 1990; 25(4):241-6. PubMed ID: 1967228
[TBL] [Abstract][Full Text] [Related]
15. Identification of two distinct intracellular sites that contribute to the modulation of multidrug resistance in P388/ADR cells expressing P-glycoprotein.
Mayer LD; Lim KT; Hartley D
J Exp Ther Oncol; 2002; 2(2):107-20. PubMed ID: 12415627
[TBL] [Abstract][Full Text] [Related]
16. Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression.
Versantvoort CH; Broxterman HJ; Pinedo HM; de Vries EG; Feller N; Kuiper CM; Lankelma J
Cancer Res; 1992 Jan; 52(1):17-23. PubMed ID: 1309222
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of the multidrug resistance genes mdr1, mdr3, and mrp in L1210 leukemia cells resistant to inhibitors of ribonucleotide reductase.
Rappa G; Lorico A; Liu MC; Kruh GD; Cory AH; Cory JG; Sartorelli AC
Biochem Pharmacol; 1997 Sep; 54(6):649-55. PubMed ID: 9310341
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists.
Yang JM; Goldenberg S; Gottesman MM; Hait WN
Cancer Res; 1994 Feb; 54(3):730-7. PubMed ID: 7905786
[TBL] [Abstract][Full Text] [Related]
19. Effect of cyclosporin A on daunorubicin accumulation in multidrug-resistant P388 leukemia cells measured by real-time flow cytometry.
Nooter K; Oostrum R; Jonker R; van Dekken H; Stokdijk W; van den Engh G
Cancer Chemother Pharmacol; 1989; 23(5):296-300. PubMed ID: 2706734
[TBL] [Abstract][Full Text] [Related]
20. Comparison of uptake of mitomycin C and KW-2149 by murine P388 leukemia cells sensitive or resistant to mitomycin C.
Kobayashi E; Okabe M; Kono M; Arai H; Kasai M; Gomi K; Lee JH; Inaba M; Tsuruo T
Cancer Chemother Pharmacol; 1993; 32(1):20-4. PubMed ID: 8096440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
